Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

DSIP peptide icon, one bubble per amino acidDSIP9 residuesWAGGDASGEEach bubble = one amino acid. Size = residue mass. Color = chemical class.

DSIP

Beginner tier: 100 mcg, daily · 3w on / 2w off · community consensus

SleepResearch
~7-8 min free plasma; ~7-8 hours carrier-bound half-life·Injection

Also known as: DSIP, Delta Sleep-Inducing Peptide, WAGGDASGE

Get an alert when FDA rules on DSIP

Follow every legal or FDA change, DSIP included. By default, alerts come as one weekly push that names the peptides.

Nine amino acids long, and it crosses the blood-brain barrier on its own. DSIP (Delta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a naturally occurring nonapeptide that promotes slow-wave delta sleep without sedation. The formal human evidence is small and old, all from IV studies between 1977 and 1992 with fewer than 20 subjects each. Community use runs subcutaneous at 100 to 300 mcg nightly, roughly 5 to 15 times the validated IV dose. Shift workers, athletes chasing recovery, and anyone tired of pharmaceutical sleep aids make up the core user base. No dependency. No grogginess. No FDA approval.

What Is DSIP?

Fourteen chronic insomniacs. That's the largest controlled human study on DSIP, a double-blind trial from 1992 [1]. Despite that modest sample, the results showed improved delta-wave sleep architecture without the REM suppression that benzodiazepines cause.

DSIP (Delta Sleep Inducing Peptide, CAS 62568-57-4) is a nonapeptide, nine amino acids, with a molecular weight of 849 Da. It crosses the blood-brain barrier through a non-competitive, non-saturable transport mechanism. In plasma, free DSIP degrades in about 7 minutes. Carrier proteins extend its functional duration to several hours, though the specific carrier has never been isolated.

The mechanism touches multiple pathways. DSIP interacts with NMDA receptors in the hypothalamus, pushing the brain toward slow-wave sleep. It also stimulates pineal acetyltransferase through alpha-1 adrenergic receptors, which increases natural melatonin synthesis. On the hormonal side, it suppresses ACTH and cortisol [2] and stimulates luteinizing hormone release [3].

Community use runs subcutaneous at 100 to 300 mcg nightly, 30 to 60 minutes before bed. That's 5 to 15 times the only validated human IV dose (~21 mcg for 70 kg). No pharmacokinetic bridging study connects these two routes. Sleep tracker data from Oura and Garmin users on r/peptides consistently shows increased deep sleep percentages. Responder variability is high; a meaningful subset reports zero effect, often attributed to product quality problems.

The research gap is real: all human trials are over 30 years old, undersized, and IV-only. A 2024 Frontiers in Pharmacology paper tested a DSIP fusion peptide in mouse models with positive results (DOI 10.3389/fphar.2024.1439536), but new human trials don't exist yet.

How DSIP Works

DSIP reaches the brain through a transport system that most peptides can't use. Blood-brain barrier crossing typically requires lipophilicity or specific receptor-mediated endocytosis. DSIP takes neither route; it uses a non-competitive, non-saturable mechanism documented by Kastin's research group. This means higher blood levels don't saturate the transport, an unusual property for a 849 Da peptide.

Once inside the CNS, DSIP works through at least three distinct pathways. First, it modulates NMDA receptors in the hypothalamus and limbic system, promoting the transition into slow-wave sleep. Unlike benzodiazepines, it doesn't suppress REM sleep. Second, it stimulates pineal acetyltransferase activity via alpha-1 adrenergic receptors. This enzyme is rate-limiting for melatonin synthesis, so DSIP effectively amplifies the body's own sleep signal.

Third, DSIP acts on the hypothalamic-pituitary-adrenal axis. It decreases basal corticotropin (ACTH) levels and blocks stress-induced ACTH release [2]. Lower ACTH means lower cortisol, which partly explains why users report reduced stress reactivity alongside better sleep.

The half-life creates confusion. Free plasma DSIP degrades in 7 to 8 minutes via aminopeptidases. But in vivo, DSIP binds carrier proteins that shield it from degradation. Functional duration extends to an estimated 6 to 8 hours. No group has isolated the specific carrier protein or its gene, which remains one of the biggest unanswered questions in DSIP pharmacology.

DSIP also stimulates hypothalamic LH-releasing hormone secretion. Measurable luteinizing hormone increases appear within 30 minutes of central administration [3]. Additional research shows suppression of lipid peroxidation and activation of endogenous antioxidant defenses, suggesting neuroprotective properties.

DSIP Benefits

  • DSIP benefits center on sleep architecture restoration and stress-hormone normalization, without the dependency risk of pharmaceutical alternatives.
  • Deeper slow-wave sleep confirmed by wearable data. Oura and Garmin users on r/peptides consistently report 15 to 30 percent increases in deep sleep metrics during active cycles.
  • Faster sleep onset without sedation. Users fall asleep quicker, but DSIP doesn't force drowsiness. The sleep cascade initiates naturally once you're in bed.
  • No dependency or withdrawal documented in any published study (review, review)[4][5]. Community reports across hundreds of threads confirm this finding.
  • Cortisol and ACTH suppression. DSIP blocks stress-induced ACTH release at the HPA axis [2], which may explain improved stress reactivity that users report by weeks 2 to 3.
  • Luteinizing hormone stimulation within 30 minutes of central administration [3]. A lesser-known benefit that makes DSIP interesting for male hormonal optimization protocols.
  • Zero morning grogginess at standard doses (100 to 200 mcg SC), unlike benzodiazepines and Z-drugs that impair next-day function.

DSIP: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 7 key studies·Research only

IV administration improved delta-wave sleep in small controlled human studies (1977-1992); effect sizes were modest and results inconsistent across labs.

Dosing studied: ~21 mcg IV (25 nmol/kg for 70 kg): the only validated human dose; SC doses are entirely extrapolated
Read the evidence (key study, limitations)

No human SC data exists. Most studies are >30 years old and underpowered. 2024 mouse-model work demonstrates DSIP fusion peptide efficacy but no new human trials.

Key Study

PMID 1299794: "Effects of DSIP on sleep of chronic insomniac patients" (double-blind, n=14, 1992); Frontiers Pharmacology 2024 (DSIP-CBBBP fusion peptide, mouse model insomnia, DOI 10.3389/fphar.2024.1439536)

Limitations

All human trials used IV administration; no human SC bioavailability data. Studies are small (n<20), >30 years old, from single research groups. Mechanism of carrier-protein binding that extends functional half-life has not been fully characterized: no carrier protein gene or precursor has been isolated. No RCTs at any community dose.

Community Experience
Moderate
3.0/5
Based on ~50-150 Reddit threads (r/peptides)

Users consistently report improved sleep architecture (deeper slow-wave sleep, faster onset, reduced night waking) without grogginess or dependency.

Community dosing: 100–250 mcg SC, 30–60 min before bed; occasional reports up to 300–500 mcg with headache risk above 300 mcg
Read the reports (what users report 5, common issues 6)

Effect variability is high; a meaningful subset reports no effect, likely due to product quality issues.

What users report (5)
  • Improved sleep onset: fall asleep faster without sedation
  • Deeper slow-wave / delta sleep confirmed on Oura/Garmin trackers
  • No grogginess or next-day impairment at 100-200 mcg
  • Perceived cortisol normalization and reduced stress reactivity
  • Non-habit-forming: no dependency or withdrawal reported
Common issues (6)
  • High responder variability: significant subset reports no effect
  • Dose-dependent headache (most common complaint, especially >300 mcg)
  • Tolerance development with continuous daily use: cycling required
  • Vivid / intense dreams can be disruptive for some users
  • Product quality inconsistency across research-grade brands
  • Rebound insomnia occasionally reported on abrupt cessation after long runs
Partially Aligned

Both science and community agree DSIP influences sleep architecture and may deepen slow-wave sleep. They diverge on route (IV only in science vs SC in community), dose (21 mcg IV vs 100-300 mcg SC), and confidence level. Community SC use is a pragmatic extrapolation with no PK validation. The core mechanism hypothesis is shared; the evidence quality for SC dosing is entirely community-derived.

DSIP Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate200 mcg
DailyTrack
Aggressive300 mcg
DailyTrack
Note:

Reconstitution math for the standard 5 mg vial: add 2 mL bacteriostatic water to get 2,500 mcg per mL (2.5 mg/mL). On a U-100 insulin syringe, each unit equals 25 mcg.

Beginner dose (100 mcg) = 4 units. Moderate dose (200 mcg) = 8 units. Aggressive dose (300 mcg) = 12 units. These are tiny volumes. You'll want a 0.5 mL insulin syringe with half-unit markings for accuracy at the beginner dose.

Inject subcutaneous 30 to 60 minutes before bed. Not at bed, not two hours before. The cascade needs time to initiate. Abdomen and upper arm are the go-to sites.

Store reconstituted vials at 2 to 8 degrees Celsius. Use within 21 days. DSIP is fragile; the peptide can degrade faster than most if exposed to heat or repeated temperature swings.

The one thing most beginners miss: if you feel nothing after two weeks at 100 mcg, check product quality before bumping the dose. DSIP quality varies more than almost any other research peptide. HPLC certificates of analysis from third-party labs are the best quality check.

Cycling Protocol

On Period
3 weeks
Off Period
2 weeks

Typical protocol is 2-4 weeks on, 2 weeks off. No dependence or withdrawal has been reported, but cycling preserves receptor sensitivity. Some users run 5 days on, 2 days off within each active week.

Calculate your DSIP dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

DSIP Protocols by Goal

beginnerCommunity3 weeks on / 2 weeks off
Introductory run
Wk 1-3
100 mcg · Nightly · Subcutaneous
Off cycle
Wk 4-5
0 mcg · None · Subcutaneous

Expected: Improved sleep onset and modest improvement in deep sleep depth. Not all users respond: if no effect by week 2, consider product quality or dose uptitration.

How to Use DSIP

  1. 1
    Remove the flip-off cap from a 5 mg DSIP vial

    Swab the rubber stopper with an alcohol wipe.

  2. 2
    Draw 2 mL of bacteriostatic water into a syringe

    Inject it slowly against the vial wall (not directly onto the powder). Let it dissolve, gently swirling if needed. Don't shake. Final concentration: 2,500 mcg per mL.

  3. 3
    Step 3

    Using a U-100 insulin syringe (29 to 31 gauge, 0.5 mL), draw your dose. Beginner: 4 units (100 mcg). Moderate: 8 units (200 mcg). Aggressive: 12 units (300 mcg).

  4. 4
    Pinch a fold of skin on your abdomen or upper arm

    Insert the needle at a 45-degree angle. Inject slowly. Release the skin fold after withdrawing the needle.

  5. 5
    Administer 30 to 60 minutes before your target bedtime

    The DSIP cascade takes time to engage the sleep architecture; injecting right at lights-out reduces the window for delta-wave initiation.

  6. 6
    Step 6

    Return the vial to the refrigerator (2 to 8 degrees Celsius). Mark the reconstitution date on the vial. Discard after 21 days. A single 5 mg vial provides approximately 25 doses at 200 mcg.

Alternative Routes

IV (intravenous)

Human clinical dose: ~21 mcg (25 nmol/kg for 70 kg); far lower than SC community doses

All formal human studies used IV administration. This is the only route with human evidence of efficacy. Not appropriate for self-administration. SC is the de facto community standard.

Subcutaneous (SC)

Community doses of 100-300 mcg SC are 5-15x higher than validated IV human doses, partially compensating for lower bioavailability and first-pass losses

BBB penetration via non-saturable transport mechanism is documented, but no SC-to-IV PK bridging study exists. Standard home-use approach. Abdomen or upper arm preferred.

Mixing your own vial? Use the DSIP reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

DSIP Stacking Protocols

Works With

Avoid

Benzodiazepines (diazepam, alprazolam, clonazepam)

Both DSIP and benzodiazepines produce CNS depression. Concurrent use risks additive sedation and unpredictable CNS depression. Benzodiazepines also suppress slow-wave sleep: directly opposing DSIP's mechanism.

Do not combine
Z-drugs (zolpidem, eszopiclone)

Same additive CNS depression concern as benzodiazepines. Z-drugs suppress deep sleep architecture; DSIP aims to restore it: concurrent use is mechanistically counterproductive.

Do not combine
ACE inhibitors / captopril-class peptidase inhibitors

DSIP is degraded by aminopeptidases. ACE inhibitors inhibit peptidase activity and may slow DSIP degradation, unpredictably extending or amplifying effects. Clinical significance unknown.

Melatonin (high dose)

DSIP stimulates endogenous melatonin synthesis via pineal acetyltransferase. High-dose exogenous melatonin (3-10 mg) combined with DSIP risks excessive melatonin activity and may suppress natural secretion long-term. Low-dose melatonin (0.5-1 mg) is less concerning.

How much does DSIP cost?

Typical price

$6.00 to $9.00 per mg

Typical $7.00

Middle half of 72 US prices for 5 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Listed as withdrawn from FDA Category 2 as of April 22, 2026. PCAC discussed it on July 24, 2026; no FDA rule has added it to the 503A bulks list

Pricing updated 2026-04-09

DSIP Side Effects

Headache is the most common complaint, and it's dose-dependent. Community reports concentrate the risk above 300 mcg, though occasional cases appear at lower doses. The mechanism isn't well understood, but reducing to 200 mcg resolves it in most users.

Every human study on DSIP was conducted intravenously between 1977 and 1992. Total humans studied across all published trials is fewer than 100. Side effect data at subcutaneous doses (100 to 300 mcg) is entirely community-derived, not clinically validated. Keep that limitation in mind when reading frequency estimates.

Published side effects from IV human studies include transient headache, mild nausea, and occasional vertigo. These were reported in early European clinical work and referenced in the 2006 review by Graf and Kastin [5]. Frequency data is sparse given the small sample sizes (n less than 20 per study).

Community-reported side effects at subcutaneous doses:

Headache (common at 300 mcg or above, uncommon at 100 to 200 mcg). Most users describe it as mild and transient. Hydration before injection helps. Persistent headache at any dose warrants stopping the protocol.

Vivid or intense dreams (frequently reported, especially in the first week). Delta-wave sleep deepening can amplify dream activity. Most users consider this a feature, not a bug. If dreams become disruptive, reducing the dose to 100 mcg or injecting 90 minutes before bed (instead of 30 to 60 minutes) may help.

Tolerance development with continuous daily use. Community experience consistently shows diminishing returns after 2 to 4 weeks of nightly use. Cycling is the standard solution: 2 to 4 weeks on, 2 weeks off. Some users run 5 days on, 2 days off within each active week to slow tolerance.

Rebound insomnia has been occasionally reported after abrupt cessation following extended daily runs. Tapering by reducing frequency before a full break may reduce this risk.

Responder variability is high. A meaningful subset of users reports zero effect. Product quality is the first variable to investigate before concluding non-response; DSIP peptide integrity is fragile.

Injection-site reactions are uncommon but possible with any subcutaneous injection. Standard site rotation (abdomen, upper arm) applies.

Contraindications: pregnancy and breastfeeding (no safety data exists for fetal or infant exposure), known hypersensitivity to DSIP, severe hypotension (DSIP may lower blood pressure through cortisol reduction), and children/adolescents (not studied in pediatric populations). Personal or family history of cancer has been cited by InnerBody's review as a precaution, cross-referencing FDA safety concerns.

Drug interactions require attention. Benzodiazepines and Z-drugs risk additive CNS depression and should not be combined with DSIP. Antihypertensive medications may see amplified effects through DSIP's cortisol reduction. Exogenous corticosteroid protocols could be disrupted, since DSIP suppresses ACTH. High-dose melatonin (3 to 10 mg) creates redundant pathway stimulation; keep melatonin at 0.5 to 1 mg if combining. ACE inhibitors may slow DSIP degradation through aminopeptidase inhibition, unpredictably extending effects.

Common Issues & Solutions

No effect after 1-2 weeks: First-pass issue is likely product quality. DSIP peptide integrity is fragile: an HPLC COA and third-party testing are the only checks. If the product is verified, try uptitrating to 200 mcg before concluding non-response.

Dose-dependent headache: The most common complaint, typically at 300 mcg+. Reduce to 200 mcg. Ensure adequate hydration before injection. Headache at 100-200 mcg is uncommon and may indicate sensitivity or a product quality issue.

Tolerance / diminishing effect after week 2: Expected with continuous daily use. Implement 5 days on / 2 days off within each cycle, or shorten active cycles to 2-3 weeks with a firm 2-week break. No formal desensitization data exists but cycling is the community standard.

Vivid or disruptive dreams: Delta-wave sleep deepening can intensify dreaming, especially in the first week. Usually self-limiting. If disruptive, reduce dose to 100 mcg or inject slightly earlier (90 min before bed) to allow the cascade to initiate before peak REM windows.

Grogginess next day: Uncommon at 100-200 mcg. More often reported at 300 mcg+. Try reducing dose. Also check reconstitution: if the vial was accidentally overdiluted or under-diluted, syringe-unit calculations may not match intended dose.

Ask AI about this page

Ask AI for a second opinion on DSIP dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no safety data exists for fetal or infant exposure
  • Known hypersensitivity to DSIP or any component of the formulation
  • Severe hypotension: DSIP may modestly lower blood pressure through stress-hormone reduction
  • Children and adolescents: not studied in pediatric populations

Drug Interactions

  • Benzodiazepines and other GABAergic sedatives: potential additive CNS depression; avoid concurrent use or reduce sedative dose
  • Antihypertensive medications: DSIP may enhance blood pressure lowering through cortisol reduction; monitor BP
  • Corticosteroids: DSIP suppresses ACTH and cortisol release, which could theoretically interfere with exogenous corticosteroid protocols
  • Melatonin supplements: overlapping mechanism via pineal acetyltransferase stimulation; combined use is likely redundant rather than dangerous

Product Quality

Recommended Monitoring

TestWhenTarget
Subjective sleep quality logNightly during protocol: rate sleep onset speed, depth, and next-day alertness on a 1-10 scaleNot listed
Wearable sleep tracker (Oura Ring, Garmin, Whoop)Continuous during protocolNot listed
AM cortisol (serum or salivary)Optional: baseline before protocol, then at week 3 of first runMorning serum cortisol: 10-20 mcg/dL (normal reference range)
LH / testosterone (optional, males)If using DSIP alongside GH secretagogue stack for performance optimizationNot listed
Subjective sleep quality log

Primary outcome measure. DSIP effect on sleep architecture is the main use case.

Wearable sleep tracker (Oura Ring, Garmin, Whoop)

Objective measurement of deep/slow-wave sleep percentage. Provides data-driven evidence of response before uptitrating dose.

AM cortisol (serum or salivary)

DSIP suppresses stress-induced ACTH and cortisol. If cortisol normalization is a protocol goal, pre/post measurement quantifies the HPA-axis effect.

LH / testosterone (optional, males)

DSIP stimulates hypothalamic LH-releasing hormone secretion. Baseline LH useful if tracking hormonal effects in combination protocols.

DSIP Before and After

Days 1-3

Most users notice faster sleep onset and more vivid dreams within the first few nights. Effects are subtle: this is not a sedative.

Week 1

Deeper sleep becomes more consistent. Morning alertness improves. Some report reduced middle-of-the-night waking.

Weeks 2-3

Sleep architecture normalizes. Cortisol patterns may improve. Cumulative recovery benefits become apparent: better mood, reduced brain fog.

Week 4+

Full benefits plateau. Most protocols call for cycling off at this point (2-4 weeks off) to maintain sensitivity.

What to Expect

Days 1 to 3: Most users notice faster sleep onset within the first few nights. Dreams may become more vivid. Don't expect sedation; DSIP initiates a sleep cascade, it doesn't knock you out. Some people feel nothing at first. Mild headache affects a minority. Morning alertness occasionally improves even on night one.

Week 1: Deeper sleep becomes more consistent. Night waking reduces. If you're wearing an Oura or Garmin, check your deep sleep percentage; many users see measurable increases by day 5 to 7. Vivid dreams may persist. Occasional headache at higher doses.

Weeks 2 to 3: Sleep architecture settles into a new baseline. Some users report lower daytime stress reactivity and better mood, consistent with DSIP's cortisol-suppressing mechanism [2]. Training recovery improves. Watch for tolerance signs by week 3 if running daily; diminishing returns are the signal to start your off-cycle.

Week 4 and beyond (off cycle): Sleep quality typically holds for 1 to 2 weeks after stopping. No withdrawal or dependency is expected based on published data and community reports. Occasional mild rebound insomnia has been reported after long unbroken daily runs. The standard community protocol calls for a 2-week break before restarting.

Detailed Timeline: Science vs Community

Days 1-3
Science

Based on IV human trials, sleep architecture changes can occur within the first administration. Cascade initiation is rapid once DSIP reaches the CNS.

Community

Most users notice faster sleep onset and somewhat more vivid dreams within the first 1-3 nights. Effects are subtle: not sedating. Some feel nothing initially.

Week 1
Science

Modulation of NMDA receptors and pineal acetyltransferase activity should produce measurable increases in slow-wave (delta) sleep proportion.

Community

Deeper sleep becomes more consistent. Night waking reduces. Sleep tracker data (Oura, Garmin) often shows increased deep/slow-wave sleep %. Morning alertness improves.

Weeks 2-3
Science

Cortisol and ACTH modulation takes longer to manifest than direct sleep effects. LH/hormone normalization may also appear in this window.

Community

Sleep architecture is well-normalized. Some report reduced daytime cortisol/stress reactivity and improved mood. Recovery from training improves. Tolerance beginnings may appear by week 3 with daily use.

Week 4+ (off cycle)
Science

No withdrawal or dependency expected based on mechanism and published data. Sleep improvements may persist somewhat after cessation.

Community

Most report sleep quality holds for 1-2 weeks after stopping. Occasional mild rebound worsening reported after long daily-use runs. 2-week break is the community standard before restarting.

Pharmacokinetics

Half-Life
8min
Bioavailability
SC: not formally quantified; crosses BBB via non-competitive non-saturable mechanism
Tmax
15-30 minutes (plasma peak after SC injection)
Data Confidence
low

Source: Kastin et al.: plasma degradation studies; functional duration extended by carrier protein binding

Pharmacokinetics: Active Dose Over Time

t½ = ~7-8 min free plasma; ~7-8 hours carrier-bound (functional duration)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
9
Molecular Weight
848.82 Da
Sequence
WAGGDASGE
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider DSIP

  • Adults with disrupted sleep architecture or difficulty reaching deep sleep
  • Shift workers needing to reset circadian patterns
  • Individuals with elevated cortisol or chronic stress affecting sleep
  • Those seeking a non-habit-forming alternative to pharmaceutical sleep aids
  • Athletes looking to optimize recovery through improved sleep quality

Related Peptides

What Changed for DSIP

  1. Regulatory

    PCAC did not back emideltide (DSIP) for the 503A list 6-7-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote is advice to FDA, not a decision. Emideltide stays off the 503A bulks list unless FDA adds it by notice-and-comment rule.

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  2. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Also covers: BPC-157, KPV, TB-500, MOTS-c, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]Effects of DSIP on sleep of chronic insomniac patients: double-blind study (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]DSIP response to human CRH in major depressive disorder: cortisol correlation (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]DSIP stimulates the release of LH via a hypothalamic site of action in the rat (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Delta-sleep-inducing peptide (DSIP): a review (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]DSIP: a still unresolved riddle: comprehensive review (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Room temperature acceptable for short periods; refrigerate at 2-8°C for long-term storage up to 24 months
After Reconstitution
Refrigerate at 2-8°C and use within 21 days; do not freeze
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

DSIP is thought to initiate delta-wave sleep architecture by triggering a downstream CNS signaling cascade, not by requiring sustained blood levels. Once the cascade is activated, it runs through the sleep period independently, which also explains why some studies found daytime DSIP administration improved the next night's sleep.

All formal human sleep studies used IV administration. SC is the standard community approach and CNS penetration has been demonstrated via non-saturable BBB transport, but no SC bioavailability data exists in humans. SC doses (100–300 mcg) are substantially higher than the IV human dose (~21 mcg for 70 kg), partly compensating for lower bioavailability.

Anecdotally, users cycle 2–4 weeks on / 2 weeks off to maintain sensitivity. No formal receptor desensitization data exists in humans, and no withdrawal syndrome or dependency has been observed in any published study.

Both work through pineal acetyltransferase pathways. DSIP stimulates endogenous melatonin synthesis while melatonin supplements provide exogenous melatonin. Concurrent use is likely redundant rather than dangerous. If using both, reduce melatonin to 0.5–1 mg to avoid excessive suppression of natural secretion.

In the US, DSIP was on the FDA's Category 2 restricted bulk drug substance list until its nominators withdrew it; FDA's page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed it (as emideltide) on July 24, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. It is sold online as a research chemical labeled "for research use only." It is not a controlled substance.